An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States (ARENA)

Bayer

Status: Completed

Conditions: Non-metastatic Prostate Cancer; Non-metastatic Castration-resistant Prostate Cancer

Treatments: Drug: Apalutamide; Drug: Darolutamide (Nubeqa, BAY1841788); Drug: Enzalutamide

Study type: Observational

Funder types: Industry

Identifiers

NCT06204302

22704

Details and patient eligibility

About

This is an observational study in which data will be collected and studied from men with non-metastatic prostate cancer (nmPC) who received their usual treatment with 'androgen receptor inhibitors' (ARIs) including darolutamide, enzalutamide, and apalutamide.

Prostate cancer is a common cancer in men that starts in the prostate gland, a male reproductive gland found below the bladder. Non-metastatic means that cancer has not yet spread to other parts of the body.

Darolutamide, enzalutamide, and apalutamide are already approved ARIs for nmPC in the United States (US). They work by blocking androgens (male sex hormones including testosterone) from attaching to proteins in cancer cells in the prostate. This helps to slow down the growth of the cancer cells. The participants will receive their treatments as prescribed by their doctors during routine medical care according to the approved product information.

Researchers want to know more about the use of ARIs and how they affect men with nmPC in the real world. Researchers will only include men who have not been treated with any new type of medication that blocks the action of male sex hormones.

The main purpose of this study is to collect and study information from men with nmPC about:

• the length of time they continued treatment with an ARI as prescribed by their doctors.
• the length of time from the start of the treatment with an ARI until the cancer spreads to other parts of the body.

Data will come from the participants' information stored in a database called Komodo Research Dataset (KRD) in the US.

The data collected will be from May 2019 to June 2023.

Researchers will only track data of eligible US men with nmPC and will follow them for a minimum of 6 months or until the end of the study.

Enrollment: 1,800 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men diagnosed with prostate cancer (≥1 claim for prostate cancer).
• Treatment with apalutamide, darolutamide or enzalutamide initiated for the first time in the nmPC stage during the patient identification period.
• Age ≥ 18 years at index date
• At least 6 months of continuous eligibility in medical and pharmacy benefits prior to the index date
• At least 6-months of continuous eligibility only in pharmacy benefits after the index date unless patient died before 6 months.

Exclusion criteria

• Patients with multiple ARIs recorded at index date
• Use of an ARI agent or abiraterone acetate prior to the index date
• Other cancer diagnosis (except prostate and skin cancer) during the 6-month baseline period
• Evidence of metastatic disease any time before or 30 days after index date.
• No claim with a diagnosis for hormone sensitive malignancy status (Z19.1) during the study period

Trial design

1,800 participants in 3 patient groups

Darolutamide

Description:

Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Darolutamide as initial treatment.

Treatment:

Drug: Darolutamide (Nubeqa, BAY1841788)

Enzalutamide

Description:

Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Enzalutamide as initial treatment.

Treatment:

Drug: Enzalutamide

Apalutamide

Description:

Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Apalutamide as initial treatment.

Treatment:

Drug: Apalutamide